Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Avoid unnecessary handling
Targetting ferroptosis for blood cell-related diseases
Most issues resolve with concentration reduction or application frequency adjustment
Common loading phase A commonly discussed experimental loading phase is: 22.5 mg per administration Twice per week Four to six weeks Common maintenance phase After the loading period, commonly circulated maintenance protocols may reduce the amount to: 22.5 mg once weekly Or 22.5 mg once every two weeks Maintenance practices vary significantly and are not supported by standardized human dose-ranging studies
Professor Sikirics research contributions include: Isolation and initial characterization of BPC-157 from human gastric secretions Extensive investigations of gastroprotective and ulcer-healing mechanisms Studies on musculoskeletal tissue repair including tendon, ligament, and muscle healing Research on cardiovascular protective effects and vascular injury healing Investigations of neuroprotective mechanisms in CNS injury models Over 400 published articles on BPC-157 and related cytoprotection concepts Professor Allan L
